LEO Pharma, "JW Pharmaceutical Atopy New drug will be promoted for clinical trials next year."
LEO Pharma, "JW Pharmaceutical Atopy New drug will be promoted for clinical trials next year."
  • Kim Min-jee
  • 승인 2019.05.22 12:45
  • 댓글 0
이 기사를 공유합니다

JW Pharmaceutical and LEO Pharma announced the 'JW1601' partnership at a ceremony marking the 60th anniversary of Korea-Denmark diplomatic relations.
JW Pharmaceutical Research Center Director Park Chan-hee introduces the strategic partnership with Denmark's LEO Pharma at a seminar marking the 60th anniversary of diplomatic ties between South Korea and Denmark at the Shilla Hotel on May 21. JW Pharmaceutical signed a technology export contract with LEO Pharma in August last year for the atopic dermatitis drug JW1601.
JW Pharmaceutical Research Center Director Park Chan-hee introduces the strategic partnership with Denmark's LEO Pharma at a seminar marking the 60th anniversary of diplomatic ties between South Korea and Denmark at the Shilla Hotel on May 21. JW Pharmaceutical signed a technology export contract with LEO Pharma in August last year for the atopic dermatitis drug JW1601.

JW Pharmaceutical has shared an excellent example of R&D cooperation between South Korean and Danish companies. 

JW Pharmaceutical introduced its partnership strategy with "LEO Pharma," a global leader in skin diseases, at a seminar marking the 60th anniversary of Korea-Denmark diplomatic ties in Seoul on May 21.

The event, co-hosted by LEO Pharma and the Danish Embassy in Seoul, was attended by more than 100 people, including Danish Crown Prince Frederic, Danish Ambassador to South Korea Thomas Lehmann, and executives from JW Pharmaceutical and LEO Pharma.

LEO Pharma showcased "Open Innovation Platform," which allows outside partners to test and evaluate candidate materials for free, and "LEO Science & Tech Hub," which transforms early-stage R&D tasks into groundbreaking solutions.

Kim Domela Kjøller, vice president of LEO Pharma Global R&D, said, "So far, I am confident in the effectiveness as well as the safety of clinical results," said Kim Domela Kjøller, vice president of LEO Pharma Global R&D. "Next year, JW Pharmaceutical's new drug atopy could go global."

"LEO Pharma had a lot of communication with JW Pharmaceutical, and we had a lot of interaction to sign the contract," said Kim. "How fast they signed the contract is a case in point that shows how well they were in harmony with Korea. Such deals are so complicated that they are rarely concluded in a year. I think it's the best partnership so far."

JW Pharmaceutical signed an agreement with LEO Pharma in August last year to export its technology to the atopic dermatitis drug JW1601. The total contract amounts to $42 million. JW Pharmaceutical is currently undergoing clinical first-phase trials.

The global market for atopic therapy was worth $4.575 billion in 2016 and is expected to grow rapidly to $7.3 billion by 2024, according to market researcher Global Data.
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • Korea IT Times: Copyright(C) 2004, Korea IT Times. .Allrights reserved.
  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • * Mobile News: m.koreaittimes.com
  • * Internet news: www.koreaittimes.com
  • * Editorial Div. 02-578-0434 / 010-2442-9446 * PR Global/AD: 82-2-578-0678.
  • * IT Times Canada: Willow St. Vancouver BC
  • 070-7008-0005
  • * Email: info@koreaittimes.com
ND소프트